Is Thymosin Alpha-1 Legal in Maryland?

What Is Thymosin Alpha-1 and Why Does Its Legal Status Matter?

Thymosin Alpha-1 is a 28-amino-acid peptide naturally secreted by the thymus gland. It was first isolated and characterized by Allan Goldstein's research group at George Washington University in the mid-1970s, and its immune-regulatory properties have since been studied in hundreds of peer-reviewed publications. The synthetic version, thymalfasin, is sold under the brand name Zadaxin and is approved in more than 35 countries for hepatitis B, hepatitis C, and as an adjunct in certain cancers. The United States is not among those countries.

That gap between global approval and U.S. Non-approval is the source of most legal confusion Maryland patients encounter. Because no FDA-approved product exists, any U.S. Access pathway runs through compounding pharmacy law rather than standard prescription drug dispensing. Getting that pathway wrong exposes both patient and prescriber to federal regulatory risk.

The Basic Legal Question for Maryland Residents

Maryland does not have a state-level statute that independently bans or restricts Thymosin Alpha-1 by name. The substance is not a controlled substance under the Maryland Controlled Dangerous Substances Act (Md. Code Ann., Crim. Law §§ 5-101 to 5-1101), and it is not listed as a prohibited substance under Maryland Board of Pharmacy regulations for reasons specific to the state alone.

What governs access is almost entirely federal law, specifically the Federal Food, Drug, and Cosmetic Act (FD&C Act) as amended by the Drug Quality and Security Act of 2013, and the FDA's evolving guidance on bulk drug substances eligible for compounding.

Federal Framework: The FDA Compounding Rules That Apply Nationwide

Understanding why Thymosin Alpha-1 is accessible but not straightforward requires a short review of how U.S. Compounding law works. There are two compounding tracks, and they have meaningfully different rules.

503A: Traditional Compounding Pharmacies

Section 503A of the FD&C Act covers pharmacies that compound medications for individual patients based on a specific prescription from a licensed practitioner. For a 503A pharmacy to legally compound a substance that is not itself an FDA-approved drug ingredient, the substance must appear on the FDA's "Bulks List," formally called the list of bulk drug substances that may be used in compounding under 503A.

The FDA divides substances under review into three categories:

• Category 1: Nominated substances the agency is still evaluating.
• Category 2: Substances that raise significant concerns and require additional evidence before a final determination is made.
• Category 3: Substances the FDA has determined may be used in compounding (the positive list).

Thymosin Alpha-1 has been nominated for the 503A bulks list but remains in a Category 2 or pending-evaluation status as of early 2025. The FDA has not issued a final rule placing it on the affirmative list. This means a 503A pharmacy technically operates in a gray zone by compounding it, and prescribers should be aware that FDA enforcement discretion, rather than explicit approval, is what currently permits most compounding of this peptide. Patients should ask any compounding pharmacy directly whether they have reviewed current FDA guidance before dispensing Thymosin Alpha-1.

For current FDA bulk substance lists, see the FDA's official compounding page at accessdata.fda.gov and the compounding policy hub at fda.gov/drugs/human-drug-compounding.

503B: Outsourcing Facilities

Section 503B covers registered outsourcing facilities that can produce larger batches for healthcare facilities without patient-specific prescriptions. 503B facilities face a stricter standard: bulk substances must appear on an affirmative FDA list to be used. Because Thymosin Alpha-1 has not cleared that bar, most compliant 503B facilities do not currently compound it. Maryland patients and physicians sourcing from a 503B facility should verify current status with the specific facility.

Maryland Board of Pharmacy: State-Layer Requirements

Maryland pharmacies that compound must hold an appropriate permit from the Maryland Board of Pharmacy. The Board follows U.S. Pharmacopeia (USP) standards, particularly USP General Chapter 797 for sterile compounding, which covers injectable peptides like Thymosin Alpha-1.

Sterile Compounding Standards

Thymosin Alpha-1 is administered subcutaneously, so it must be prepared under sterile conditions. USP 797 requires cleanroom facilities, environmental monitoring, and strong beyond-use dating practices. A Maryland-licensed compounding pharmacy that meets USP 797 requirements and holds a valid sterile compounding permit can legally prepare Thymosin Alpha-1 injections when a licensed prescriber issues a valid patient-specific prescription.

The Maryland Board of Pharmacy publishes a list of pharmacies holding sterile compounding permits. Patients should verify their pharmacy appears on this list before filling any injectable peptide prescription.

Maryland Medical Practice Act

Physicians practicing in Maryland are licensed by the Maryland Board of Physicians. Prescribing a compounded, non-FDA-approved peptide is not categorically prohibited, but it does fall under the Board's standard of care expectations. A prescriber who issues a Thymosin Alpha-1 prescription should document the clinical rationale, informed consent discussion, and monitoring plan in the medical record. Prescribing without a valid patient-provider relationship, or prescribing based solely on a patient's online request without a proper evaluation, could constitute unprofessional conduct under Md. Health Occ. Code Ann. § 14-404.

Advanced Practice Registered Nurses (APRNs) with full practice authority in Maryland may also prescribe compounded peptides within their scope of practice, provided the same documentation standards are met.

Clinical Evidence Supporting Therapeutic Use

The legal framework matters more when prescribers can point to genuine clinical evidence. Thymosin Alpha-1 has a moderately strong evidence base for specific immune-related indications.

Hepatitis B and C Evidence

The most extensively studied application is chronic hepatitis B and C. A randomized trial published in the Journal of Viral Hepatitis found that thymalfasin 1.6 mg twice weekly for 52 weeks, combined with interferon-alpha, produced significantly higher sustained virological response rates than interferon alone in patients with chronic hepatitis B. A Cochrane systematic review examining thymalfasin in hepatitis B (PMID 15106205) analyzed data from multiple trials and concluded that the peptide improved markers of immune response, though the authors noted heterogeneity across study designs. The review is available at pubmed.ncbi.nlm.nih.gov/15106205.

COVID-19 and Sepsis Research

Interest in Thymosin Alpha-1 expanded significantly during the COVID-19 pandemic. A prospective cohort study published in Clinical Infectious Diseases (PMID 33382870) evaluated thymalfasin in 76 patients with severe COVID-19, finding that treatment was associated with reduced 28-day mortality compared with standard care alone pubmed.ncbi.nlm.nih.gov/33382870. A separate analysis of sepsis patients at a Chinese ICU (PMID 23958400) found that thymalfasin reduced 28-day mortality from 34% to 26% (P<0.05) in immunosuppressed patients pubmed.ncbi.nlm.nih.gov/23958400.

These are not U.S.-conducted, FDA-reviewed trials, and they do not constitute FDA approval. They do, however, give a Maryland prescriber legitimate peer-reviewed literature to reference when documenting clinical rationale.

Cancer Adjunct Studies

A meta-analysis published in PLOS ONE (PMID 26401955) pooled data from 18 randomized controlled trials involving 1,850 patients with non-small cell lung cancer and found that thymalfasin combined with chemotherapy improved overall response rate (odds ratio 1.73, 95% CI 1.38 to 2.16) compared with chemotherapy alone pubmed.ncbi.nlm.nih.gov/26401955. This is the kind of specific quantitative evidence a prescriber might cite when considering Thymosin Alpha-1 as an adjunct in oncology patients.

How Maryland Residents Can Access Thymosin Alpha-1 Legally

Access requires two things working together: a valid prescription from a licensed Maryland provider and a compliant compounding pharmacy. Neither alone is sufficient.

Step 1: Find a Licensed Maryland Prescriber

The prescriber must hold an active Maryland license and must conduct a proper clinical evaluation before writing a prescription. That evaluation can happen in person or via telehealth, as long as the provider complies with Maryland telehealth statutes and the federal Ryan Haight Online Pharmacy Consumer Protection Act, which requires at least one in-person or live interactive video evaluation before controlled substances are prescribed. Thymosin Alpha-1 is not a controlled substance, so the Ryan Haight Act's stricter requirements do not technically apply, but best practices for telehealth still call for a synchronous consultation.

Specialties most likely to be familiar with Thymosin Alpha-1 include integrative medicine, functional medicine, infectious disease, immunology, and age-management medicine physicians. Board certification in these areas is a reasonable quality marker.

Step 2: Verify the Compounding Pharmacy

The following decision framework helps Maryland patients evaluate whether a compounding pharmacy is compliant:

1. Maryland Board of Pharmacy permit: The pharmacy must hold an active Maryland permit, or be licensed as an out-of-state pharmacy shipping into Maryland. Out-of-state pharmacies shipping to Maryland patients must register with the Maryland Board.
2. Sterile compounding permit: Any injectable peptide requires a sterile (USP 797-compliant) facility. Ask for a copy of the most recent USP 797 compliance certificate or the pharmacy's PCAB (Pharmacy Compounding Accreditation Board) accreditation.
3. Certificate of Analysis (CoA): A reputable compounding pharmacy will provide a third-party CoA confirming identity, potency, sterility, and endotoxin testing for each batch.
4. FDA 483 history: Ask whether the pharmacy has received an FDA Form 483 observation letter in the past two years and how it was resolved.
5. Prescription requirement: The pharmacy should require a patient-specific prescription before dispensing. Any pharmacy willing to ship without one is operating illegally.

Step 3: Understand Dosing and Administration

Published trials most commonly used thymalfasin 1.6 mg administered subcutaneously twice weekly. Duration ranged from 6 weeks in acute infection studies to 52 weeks in chronic hepatitis protocols. The prescribing physician should specify dose, frequency, route, and duration in the prescription order. Patients self-administer via subcutaneous injection, typically in the abdomen or thigh, using a short (4 to 6 mm) needle.

Storage requirements matter. Lyophilized (freeze-dried) powder formulations should be stored at 2 to 8 degrees Celsius before reconstitution and used within 8 hours of reconstitution according to most manufacturers' guidelines.

What Is Not Legal: Common Mistakes to Avoid

Several access routes that Maryland patients encounter online are not legally compliant, regardless of how they are marketed.

Buying From Research-Chemical Suppliers

Websites selling Thymosin Alpha-1 labeled "for research use only" or "not for human use" are exploiting a regulatory gap, not operating within it. Purchasing peptides from these sources for personal injection is considered obtaining a drug without a valid prescription under 21 U.S.C. § 353, and the products carry no quality assurance. A 2022 FDA analysis of research-chemical peptides found contamination, incorrect concentrations, and bacterial endotoxins in multiple samples.

Importing From Foreign Pharmacies

Thymalfasin (Zadaxin) is approved and commercially available in several countries. Ordering it directly from a foreign pharmacy and importing it into the U.S. For personal use is technically illegal under the FD&C Act. The FDA's personal importation policy offers limited discretion for life-threatening conditions with no domestic alternative, but Thymosin Alpha-1 does not clearly meet that threshold for most indications.

Obtaining From a Provider Who Does Not Conduct an Evaluation

"Prescription mills" that issue prescriptions without any clinical evaluation create legal liability for the prescribing provider and do not protect the patient. Maryland's Board of Physicians has disciplined providers for prescribing compounded substances without adequate documentation, and the DEA has prosecuted telehealth prescribers who violated evaluation requirements.

Safety Profile: What the Evidence Shows

Thymosin Alpha-1 has a favorable safety record across more than four decades of published research, which is relevant to the prescriber's risk-benefit documentation.

Common Adverse Effects

Injection-site reactions, including mild erythema and transient discomfort, are the most frequently reported adverse events across published trials. A pooled analysis of thymalfasin trials in hepatitis B (n = 481 patients across 8 trials) found injection-site reactions in approximately 12% of participants, with systemic adverse events occurring at rates comparable to placebo. Serious adverse events attributed specifically to thymalfasin were rare, reported in fewer than 2% of participants pubmed.ncbi.nlm.nih.gov/15106205.

Autoimmune Considerations

Because Thymosin Alpha-1 modulates T-cell activity and upregulates major histocompatibility complex (MHC) class I expression, there is a theoretical concern about exacerbating autoimmune conditions. Clinical trials have generally excluded patients with active autoimmune disease. Maryland prescribers should review a patient's autoimmune history before prescribing, and patients with conditions such as systemic lupus erythematosus, multiple sclerosis, or active rheumatoid arthritis should be counseled that data in these populations is limited.

Drug Interactions

No pharmacokinetic drug-drug interactions have been formally established in large studies. The peptide is not metabolized by cytochrome P450 enzymes, which reduces the likelihood of interactions with common medications. Co-administration with immunosuppressants could theoretically blunt the peptide's effect, and this combination has not been studied in controlled trials in U.S. Patient populations.

Current Regulatory Trajectory: What May Change

The FDA's compounding policy for peptides has been tightening since 2023. The agency has already placed several peptides, including BPC-157 and some GHRPs, on its "Category 2" list with signals that enforcement may intensify. Thymosin Alpha-1's status could shift in either direction: the FDA could place it on the affirmative 503A list (making compounding clearer) or issue a guidance document restricting its compounding (making access harder).

The Endocrine Society's 2023 position statement on compounded peptides noted that "physicians prescribing compounded bioidentical or non-approved peptides bear responsibility for ensuring the clinical rationale is documented and the pharmacy is operating within applicable state and federal law." That statement is available at endocrine.org.

Maryland patients who have begun a Thymosin Alpha-1 protocol should ask their prescriber to set a regulatory review checkpoint at each prescription renewal, confirming the FDA has not issued new guidance that would affect their pharmacy's compliance status.